viewArix Bioscience PLC

Arix Bioscience Plc - Notice of Results

Arix Bioscience Plc - Notice of Results

Arix Bioscience Plc - Notice of Results

PR Newswire

Arix Bioscience plc

Notice of Results

LONDON, 20 March 2019: Arix Bioscience plc (LSE: ARIX), a global healthcare and life science company supporting medical innovation, will announce its annual results for the year ended 31 December 2018 on Thursday, 28 March 2019.

Joe Anderson, CEO and James Rawlingson, CFO, will host a breakfast briefing and call for analysts at 09:30 GMT on the day of the results at Stifel, 150 Cheapside, London, EC2V 6ET.

Details of the webcast will be available on request. The webcast will be recorded and a replay will be available on the company website.

– ENDS –


For more information on Arix, please contact:

Arix Bioscience plc

Charlotte Parry, Head of Investor Relations
+44 (0)20 7290 1072
[email protected]  

Optimum Strategic Communications

Mary Clark, Supriya Mathur
+44 (0) 203 950 9144
[email protected]

About Arix Bioscience plc

Arix Bioscience plc is a global healthcare and life science company supporting medical innovation. Headquartered in London and with an office in New York, Arix Bioscience sources, finances and builds world class healthcare and life science businesses addressing medical innovation at all stages of development. Operations are supported by privileged access to breakthrough academic science and strategic relationships with leading research accelerators and global pharmaceutical companies.

Arix Bioscience plc is listed on the Main Market of the London Stock Exchange. For further information, please visit www.arixbioscience.com

Quick facts: Arix Bioscience PLC

Price: 104.5

Market: LSE
Market Cap: £141.65 m

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Arix Bioscience acquires stake in novel firm developing sickle cell treatment

Arix Bioscience PLC (LON:ARIX) investment associate John Cassidy talks Proactive London through its decision to invest US$15mln (£11.3mln) in Imara - a firm which is developing treatments for sickle cell disease. Through the deal Arix receives a 10% stake in the company while also...

on 19/3/19